General Callout
Nunc dolor esse suscipit eros eros ullamco dolor. Duis velaliquam sunt urna, tempuribud doming quis, laboris ultricies ultricies urna laboris. Nostrud pulvinar nostrud elit sunt ex exercitation magna tempuribud laboris ea ex nunc sed exercitation ea laboris dignissim.
Accordion
Quis harmud ea commodo voluptate dolor urna providerent tempor amet dignissim velit consectetur harmud sint doming, urna magna velit sed commodo urna sint sunt nunc. Nunc consectetur laboris harmud dolore exercitation sed magna laboris nulla velit velaliquam ultricies. Dignissim adipiscing, sed duis ultricies sint voluptate providerent nunc nisi.
Heading 1
Pariatur aliquip quis doming sint eros sit nulla consectetur velit quis consectetur ea dolore quis, eros voluptate commodo quis doming sint aliquip esse tempuribud quis velit ut ut aliquip ex quis, ullamco eu in. Nisi nulla amet quis tempor tempuribud aliquip. Adipiscing nostrud eu fugiat, duis quis sunt eu, providerent sed quis pariatur velit amet dolore in.
Heading 2
Pariatur aliquip quis doming sint eros sit nulla consectetur velit quis consectetur ea dolore quis, eros voluptate commodo quis doming sint aliquip esse tempuribud quis velit ut ut aliquip ex quis, ullamco eu in. Nisi nulla amet quis tempor tempuribud aliquip. Adipiscing nostrud eu fugiat, duis quis sunt eu, providerent sed quis pariatur velit amet dolore in.
Call to action
Esse suscipit in eros ea sed voluptate dolore, harmud nisi, dolore ultricies fugiat amet doming ut sint ut adipiscing. Sit velit velaliquam ex nunc ut voluptate
Status:
Concluded with an LOI
Manufacturer:
AstraZeneca Canada Inc.
Indication:
Ovarian Cancer, monotherapy for the maintenance treatment of female adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy
Last updated October 21, 2020
Status:
Concluded with an LOI
Manufacturer:
Alexion Pharma GmbH
Indication:
Lysosomal acid lipase deficiency
Last updated October 21, 2020
Status:
Concluded with an LOI
Manufacturer:
Hoffmann-La Roche Ltd.
Indication:
Multiple Indications
Last updated October 14, 2020
Contrave (naltrexone hydrochloride and bupropion hydrochloride)
Status:
Negotiations were not pursued
Manufacturer:
Bausch Health, Canada Inc.
Indication:
Chronic weight management
Last updated October 13, 2020
Status:
Concluded with an LOI
Manufacturer:
Sanofi-Aventis Canada Inc.
Indication:
Diabetes Mellitus, Type 1 & 2
Last updated September 30, 2020
Adcetris (brentuximab vedotin)
Status:
Concluded with an LOI
Manufacturer:
Seattle Genetics Inc.
Indication:
Peripheral T-cell Lymphoma (PTCL)
Last updated September 21, 2020
Tecentriq & Avastin (Atezolizumab & Bevacizumab)
Status:
Negotiations were not pursued
Manufacturer:
Hoffmann-La Roche Ltd.
Indication:
Non-Squamous Non-Small Cell Lung Cancer
Last updated September 1, 2020
Mylotarg (gemtuzumab ozogamicin)
Status:
Concluded with an LOI
Manufacturer:
Pfizer Canada ULC
Indication:
Acute Myeloid Leukemia (AML)
Last updated August 12, 2020
Status:
Concluded with an LOI
Manufacturer:
Paladin Labs Inc.
Indication:
Prophylaxis of Organ Rejection in Allogenic Kidney or Liver Transplant Adult Patients
Last updated July 30, 2020
Lutathera (lutetium 177 dotatate)
Status:
Concluded with an LOI
Manufacturer:
Advanced Accelerator Applications
Indication:
Gastroenteropancreatic neuroendocrine tumors (GEP-NETs)
Last updated July 29, 2020